Axbio Inc.

Analysis

Axbio Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to GIAMMONA, FRANCESCA FILIPPA, who is the busiest examiner for the company. The prosecution profile is highly focused, with only a solitary distinct examiner and a lone distinct art unit involved. This specific administrative group indicates that the company's current technical focus is situated within a niche of the biotechnology sector. The active office action is the only matter currently pending for the company.

GIAMMONA, FRANCESCA FILIPPA is responsible for 1 pending office action, which constitutes the entirety of the company's current workload at the USPTO. With only one distinct examiner, the company can concentrate its efforts on addressing the specific concerns of a single individual. The active case represents the company's current path toward securing intellectual property in the Biotechnology & Pharmaceuticals field. Because there is only a single distinct art unit and one distinct examiner, the prosecution environment is straightforward and lacks the administrative complexity of larger portfolios. This focused workload is the central element of the company's current patent strategy.